207 filings
Page 7 of 11
8-K
0ysldgb34
1 Oct 14
Other Events
12:00am
8-K
1m3dfvb3
17 Sep 14
IntelGenx to Present at Singular Research 9th Annual Best of the Uncovereds Conference
12:00am
8-K
fix7g6d0u4upo9gq603g
21 Aug 14
IntelGenx to Present at the Rodman & Renshaw Global Investment Conference
12:00am
8-K
z5b17b562pu tloc1rjc
18 Jul 14
Other Events
12:00am
8-K
fq12u
15 Jul 14
IntelGenx Announces Management Changes
12:00am
8-K
qzjwa1
1 Jul 14
IntelGenx Announces Equity Analyst Coverage by H.C. Wainwright
12:00am
8-K
zdoo6j xqh4g74
21 May 14
Other Events
12:00am
8-K
sznft3w1 r4bw
8 May 14
Submission of Matters to a Vote of Security Holders
12:00am
8-K
her5 q8ynp8fb
30 Apr 14
IntelGenx Announces Government of Canada Funding for CNS VersaFilm™ Project
12:00am
8-K
ijao0vb
28 Apr 14
Other Events
12:00am
8-K
f9fymx
24 Apr 14
IntelGenx and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm™ Product
12:00am
8-K
rxfrwaw0jea lwvzz
16 Apr 14
IntelGenx Announces Receipt of an Additional U.S. Patent Allowance Related To Proprietary Technology
12:00am
8-K
6b5hwc7whk3
3 Mar 14
Other Events
12:00am
8-K
iykvelxjcdvorfneea
26 Feb 14
IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related To Proprietary Technology
12:00am
8-K
fcyne7l2b
24 Feb 14
IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm™ Tadalafil Product
12:00am
8-K
ggb2p01
21 Feb 14
Regulation FD Disclosure
12:00am
8-K
crf3xcda
4 Feb 14
IntelGenx and RedHill Biopharma Receive Complete Response Letter from FDA for VersaFilm™ Oral Film Product for Acute Migraines
12:00am
8-K
wwothy8b3e2q
13 Jan 14
IntelGenx Announces Additional Development And Commercialization Agreement With Par Pharmaceutical, Inc. For Two More Products
12:00am
8-K
mk67sy
16 Dec 13
IntelGenx Closes $3.5 Million Public Offering
12:00am
8-K
0t1g7gdbw 4jt
12 Dec 13
IntelGenx Announces Public Offering of $3,500,000 of Common Stock
12:00am